Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS)

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026 · see citing works

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467 · see citing works

The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels

Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439 · see citing works

High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction<SUBTITLE>The IDEAL Study: A Randomized Controlled Trial</SUBTITLE>

Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548 · see citing works

High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study

Walldius, G., Jungner, I., Holme, I., AASTVEIT, A. H., Kolar, W., & Steiner, E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07098-2 · Cited by 1,227 · see citing works

Clinical utility of different lipid measures for prediction of coronary heart disease in men and women

Ingelsson, E., Schaefer, E. J., Contois, J. H., McNamara, J. R., Sullivan, L., Keyes, M. J., Pencina, M. J., Schoonmaker, C., Wilson, P. W. F., D’Agostino, R. B., et al. (2007) · JAMA · doi:10.1001/jama.298.7.776 · Cited by 608 · see citing works

The apoB/apoA‐I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid‐lowering therapy – a review of the evidence

WALLDIUS, G., & JUNGNER, I. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01643.x · Cited by 583 · see citing works

Relation Between Baseline and On-Treatment Lipid Parameters and First Acute Major Coronary Events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

Gotto, A. M., Whitney, E. J., Stein, E. A., Shapiro, D. R., Clearfield, M. B., Weis, S. E., Jou, J. Y., Langendörfer, A., Beere, P. A., Watson, D. J., et al. (2000) · Circulation · doi:10.1161/01.cir.101.5.477 · Cited by 562 · see citing works

High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study

Walldius, G., Jungner, I., Holme, I., AASTVEIT, A. H., Kolar, W., & Steiner, E. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00666-9 · Cited by 534 · see citing works

Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men

Pischon, T., Girman, C. J., Sacks, F. M., Rifai, N., Stampfer, M. J., & Rimm, E. B. (2005) · Circulation · doi:10.1161/circulationaha.104.532499 · Cited by 514 · see citing works

Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel

Barter, P. J., Ballantyne, C. M., Carmena, R., Cabezas, M. C., Chapman, M. J., Couture, P., Graaf, J. D., Durrington, P. N., Færgeman, O., Frohlich, J., et al. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01616.x · Cited by 463 · see citing works

Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment

Sniderman, A. D., Furberg, C. D., KEECH, A. C., van Lennep, J. R., Frohlich, J., Jungner, I., & Walldius, G. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12663-3 · Cited by 457 · see citing works

International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material

Marcovina, S. M., Albers, J. J., Henderson, L. O., & Hannon, W. H. (1993) · Clinical Chemistry · doi:10.1093/clinchem/39.5.773 · Cited by 342 · see citing works

Low-Density Lipoprotein, Non-High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering Therapy

Grundy, S. M. (2002) · Circulation · doi:10.1161/01.cir.0000038419.53000.d6 · Cited by 309 · see citing works

The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk

Walldius, G., Jungner, I., AASTVEIT, A. H., Holme, I., Furberg, C. D., & Sniderman, A. D. (2004) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2004.254 · Cited by 287 · see citing works

A national record linkage to study acute myocardial infarction incidence and case fatality in Sweden

Hammar, N., Alfredsson, L. S., Rosén, M., Spetz, C.-L., Kahan, T., & Ysberg, A. ‐. (2001) · International Journal of Epidemiology · doi:10.1093/ije/30.suppl_1.s30 · Cited by 251 · see citing works

Relationship Between Lipid Levels and Clinical Outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Trial

Simes, R. J., Marschner, I. C., Hunt, D. U., Colquhoun, D., SULLIVAN, D. R., Stewart, R., Hague, W. E., KEECH, A. C., Thompson, P., White, H. D., et al. (2002) · Circulation · doi:10.1161/hc1002.105136 · Cited by 250 · see citing works

International federation of clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of international reference material

Marcovina, S. M., Albers, J. J., Kennedy, H., Mei, J. V., Henderson, L. O., & Hannon, W. H. (1994) · Clinical Chemistry · doi:10.1093/clinchem/40.4.586 · Cited by 243 · see citing works

Nonfasting Apolipoprotein B and Triglyceride Levels as a Useful Predictor of Coronary Heart Disease Risk in Middle-Aged UK Men

Talmud, P. J., Hawe, E., Miller, G. J., & Humphries, S. E. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000035521.22199.c7 · Cited by 233 · see citing works

Role of the Apolipoprotein B–Apolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A Case–Control Analysis in EPIC-Norfolk

van der Steeg, W. A., Boekholdt, S. M., Stein, E. A., El-Harchaoui, K., Stroes, E. S. G., Sandhu, M. S., Wareham, N. J., Jukema, J. W., Luben, R., Zwinderman, A. H., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-9-200705010-00007 · Cited by 165 · see citing works

Apolipoprotein B and A-I values in 147 576 Swedish males and females, standardized according to the World Health Organization–International Federation of Clinical Chemistry First International Reference Materials

Jungner, I., Marcovina, S. M., Walldius, G., Holme, I., Kolar, W., & Steiner, E. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.8.1641 · Cited by 154 · see citing works

Improving Prediction of Ischemic Cardiovascular Disease in the General Population Using Apolipoprotein B

Benn, M., Nordestgaard, B. G., Jensen, G. B., & Tybjærg‐Hansen, A. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000255580.73689.8e · Cited by 152 · see citing works

Apolipoprotein B/Apolipoprotein A-I in Relation to the Metabolic Syndrome and Change in Carotid Artery Intima-Media Thickness During 3 Years in Middle-Aged Men

Wallenfeldt, K., Bokemark, L., Wikstrand, J., Hulthe, J., & Fagerberg, B. (2004) · Stroke · doi:10.1161/01.str.0000140629.65145.3c · Cited by 125 · see citing works

Hypertensive Retinal Vascular Changes: Relationship to Left Ventricular Hypertrophy and Arteriolar Changes Before and After Treatment

Dahlöf, B., Stenkula, S., & Hansson, L. (1992) · Blood Pressure · doi:10.3109/08037059209065122 · Cited by 106 · see citing works

Errors that result from using the TC/HDL C ratio rather than the apoB/apoA‐I ratio to identify the lipoprotein‐related risk of vascular disease

Sniderman, A. D., Junger, I., Holme, I., AASTVEIT, A. H., & Walldius, G. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01649.x · Cited by 104 · see citing works

ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects

Sierra-Johnson, J., Romero‐Corral, A., Somers, V. K., López-Jiménez, F. A., Walldius, G., Hamsten, A., Hellénius, M.-L., & Fisher, R. M. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm360 · Cited by 96 · see citing works

Comparison of Apolipoprotein-B/Apolipoprotein-AI in Subjects With Versus Without the Metabolic Syndrome

Sierra‐Johnson, J., Somers, V. K., Kuniyoshi, F. H. S., et al. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.06.029 · Cited by 84 · see citing works

Apolipoprotein B and A-I in relation to serum cholesterol and triglycerides in 43 000 Swedish males and females

Jungner, I., Walldius, G., Holme, I., Kolar, W., & Steiner, E. (1992) · International Journal of Clinical & Laboratory Research · doi:10.1007/bf02591655 · Cited by 80 · see citing works

ApoB but not LDL‐cholesterol is reduced by exercise training in overweight healthy men. Results from the 1‐year randomized Oslo Diet and Exercise Study

Holme, I., Høstmark, A. T., & Anderssen, S. A. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01806.x · Cited by 65 · see citing works

Apolipoprotein-B, Low-Density Lipoprotein Cholesterol, and the Long-Term Risk of Coronary Heart Disease in Men

St‐Pierre, A., Cantin, B., Dagenais, G. R., Després, J., & Lamarche, B. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.10.060 · Cited by 65 · see citing works

Imaging of the vasa vasorum

Granada, J. F., & Feinstein, S. B. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1157 · Cited by 65 · see citing works

High cholesterol and triglyceride values in Swedish males and females: increased risk of fatal myocardial infarction. First report from the AMORIS (Apolipoprotein related MOrtality RISk) study.

Walldius, G., Jungner, I., Kolar, W., et al. (1992) · PubMed · Cited by 55 · see citing works

Commentary: Lung cancer and tobacco consumption

Doll, S. R. (2001) · International Journal of Epidemiology · doi:10.1093/ije/30.1.30 · Cited by 27 · see citing works

Are geographical differences and time trends in myocardial infarction incidence in sweden real? Validity of hospital discharge diagnoses

Hammar, N., LARSEN, F. F., & Fairé, U. D. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90216-x · Cited by 25 · see citing works

Impact of follow‐up time and re‐measurement of the electrocardiogram and conventional cardiovascular risk factors on their predictive value for myocardial infarction

Moller, C. S., Zethelius, B., Sundström, J., & Lind, L. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01642.x · Cited by 22 · see citing works

Establishing the benefit of statins in low-to-moderate—risk primary prevention: The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

Gotto, A. M. (2007) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2007.02.002 · Cited by 14 · see citing works

Is it time to discard the apo B:apo A-I ratio as a predictor of cardiovascular disease?

Sierra‐Johnson, J., & Fisher, R. M. (2007) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1040 · Cited by 7 · see citing works

WO3-OR-3 SYSTEMIC GENE TRANSFER OF STABILIZED CONSTITUTIVELY ACTIVATED HYPOXIA-INDUCIBLE FACTOR-1 TARGETED TO ENDOTHELIUM AUGMENTS ISCHEMIC NEOVASCULARIZATION

Tal, R., Rofe, K., Peled, M., et al. (2007) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(07)70955-8 · Cited by 1 · see citing works

A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk

Sniderman, A. D., Williams, K., Contois, J. H., Monroe, H. M., McQueen, M. J., de Graaf, J., & Furberg, C. D. (2011) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.959247 · Cited by 659 · see citing works

Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists

Davidson, M. H., Ballantyne, C. M., Jacobson, T. A., Bittner, V. A., Braun, L. T., Brown, A. S., Brown, W. V., Cromwell, W. C., Goldberg, R. B., McKenney, J. M., et al. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.07.005 · Cited by 262 · see citing works

A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias.

de Graaf, J., Couture, P., & Sniderman, A. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0982 · Cited by 80 · see citing works

Use of reclassification for assessment of improved prediction: an empirical evaluation

Tzoulaki, I., Liberopoulos, G., & Ioannidis, J. P. A. (2011) · International Journal of Epidemiology · doi:10.1093/ije/dyr013 · Cited by 70 · see citing works

Lipoprotein Biomarkers and Risk of Cardiovascular Disease: A Laboratory Medicine Best Practices (LMBP) Systematic Review

Sandhu, P. K., Musaad, S. M. A., Remaley, A. T., Buehler, S. S., Strider, S., Derzon, J. H., Vesper, H. W., Ranne, A., Shaw, C. S., & Christenson, R. H. (2016) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2016.021006 · Cited by 55 · see citing works

Update on the laboratory investigation of dyslipidemias

Ramasamy, I. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.01.015 · Cited by 50 · see citing works

Assessing the incremental role of novel and emerging risk factors.

Cook, N. R. (2010) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-010-0084-x · Cited by 39 · see citing works

Eucaloric diets enriched in palm olein, cocoa butter, and soybean oil did not differentially affect liver fat concentration in healthy participants: a 16-week randomized controlled trial.

Stonehouse, W., Sergi, D., Benassi-Evans, B., James-Martin, G., Johnson, N., Thompson, C. H., & Abeywardena, M. (2021) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqaa347 · Cited by 16 · see citing works

Lp(a) lipoprotein and pre‐β1‐lipoprotein in patients with coronary heart disease

Berg, K., Dahlén, G. H., & Frick, M. H. (1974) · Clinical Genetics · doi:10.1111/j.1399-0004.1974.tb00657.x · Cited by 319 · see citing works

Lipoprotein Lp(a) in lipoprotein spectrum indentified by Lipoprint LDL system.

Oravec, S., Dostal, E., & Gruber, K. (2013) · PubMed · Cited by 6 · see citing works

[Hyperlipoprotein (a)-emia determined by genetic polymorphisms in apolipoprotein (a) gene].

Ichinose, A. (2008) · PubMed · Cited by 2 · see citing works

Abstract 14163: Oxidized Phospholipids and Lipoprotein-Associated Phospholipase A2 in Plasma, ApoB-containing and ApoAI -containing Lipoprotein Subfractions in Patients with Familial Hypercholesterolemia: Effect of LDL Apheresis

Arai, K., Orsoni, A., Miller, E. R., et al. (2010) · Circulation

Plasma lipoprotein(a) levels in familial defective ApoB

Evans, D. G., Beil, F. U., & Mann, W. A. (2014) · Clinical Lipidology · doi:10.2217/clp.14.20